Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Link
http://link.springer.com/content/pdf/10.1186/s40360-018-0267-5.pdf
Reference16 articles.
1. Gross CC, Ahmetspahic D, Ruck T, Schulte-Mecklenbeck A, Schwarte K, Jörgens S, Scheu S, Windhagen S, Graefe B, Melzer N, Klotz L, Arolt V, Wiendl H, Sven G. Meuth SG, Alferink J. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurology Neuroimmunology and Neuroinflammation 2016 Oct12;3(6):e289. https://doi.org/10.1212/NXI.0000000000000289
2. Hardova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trials results and considerations for use. Ther Adv Neurol Disord. 2015;8(1):31–45.
3. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. CHEST. 2010;137(5):1164–71.
4. Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med. 2004;25:133–40.
5. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Hardova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertic BI, Lake SL, Margolin DH, Panzara MA, Compston DAS. Alemtuzumab versus interferon beta 1a as a first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis;Pharmaceutics;2023-05-22
2. Recurrent intracerebral hemorrhage due to alemtuzumab treatment in a patient with multiple sclerosis: case report;Acta Neurologica Belgica;2022-04-26
3. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease;BMC Neurology;2022-03-09
4. Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors;European Journal of Neurology;2021-08-20
5. Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report;BMC Pediatrics;2021-05-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3